News and Trends 25 Aug 2022
Zelluna Immunotherapy announces investment from Takeda Ventures, Inc.
Zelluna Immunotherapy, a company focused on allogenic T-cell Receptor Natural Killer (TCR-NK) cells to treat cancer has today (August 25) announced an investment from Takeda Ventures, Inc. (TVI), the strategic…